



RHYTHM[™]
BIOSCIENCES



confidential use only

Placement Issue Investor Presentation

18 AUGUST 2025

Disclaimer

This presentation has been prepared by **Rhythm Biosciences Limited** (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.

This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. Rhythm makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward-looking statements) expressed in this presentation are subject to change without notice. Rhythm and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from or for any omissions from this presentation, except liability under statute that cannot be excluded.

This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer, invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of Rhythm. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by Rhythm or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.

About Rhythm Biosciences



We are committed to saving lives through the evaluation of cancer risk and early detection of cancers.



Early detection of cancer gives individuals the best possible opportunity for favorable treatment outcomes.


Addressing large under-served global markets worth >USD\$50bn and heavily supported by public and private health care systems.

geneType™ commercially available now and ColoSTAT® anticipated commercial launch in Q4 CY2025.

Patent protected, fully characterised proteomic, genomic technology that can be readily adopted in routine laboratories.

A valuable development pipeline of high quality, impactful cancer risk assessment and detection products.


Corporate overview



CORPORATE SNAPSHOT

ASX Code	RHY
Share Price (13 August 2025)	\$0.105
Shares on Issue (14 August 2025)	284,081M
Unlisted & Listed Options (14 August 2025)	53.4M
Market Capitalisation	\$29.83M
Cash in Bank (30 June 2025)	\$1.4M
Top 20 Shareholders % of Company	42.84%

SHARE PRICE CHART - ASX:RHY



BOARD AND MANAGEMENT

David Atkins, PhD
CEO & MD



Former CEO of Congenica (UK) & Synevo Diagnostics, Sr. Executive at Johnson & Johnson and Danaher.

Founder of Veridex – cancer molecular and cellular diagnostics (USA).

Experience in product development and commercial leadership in the global medical device and diagnostic industry.

Otto Buttula
Non-Executive Chairman
(Retiring at 2025 AGM)



Extensive financial, investment, IT & biotech experience.

Co-Founder and CEO of IWL (ASX: IWL); Founder / former CEO of Investors Mutual.

Formerly a Director of Imugene (ASX:IMU), Chairman of Investorfirst, now HUB (ASX: HUB), HITIQ (ASX: HIQ) & Oncosil Medical (ASX: OSL).

Sue MacLeman
Non-Executive Director



30 years in Pharma, Biotech and Medtech including Amgen, BMS and Merck and SME's.

Experienced Board member, former CEO of NASDAQ, ASX, & AIM entities. Currently Chair of Medicines Australia, NED & Chair at Viral Vector Manufacturing Facility, Smartways Logistics, Healthcare Translation Group, ATSE & OMICO & member of the National Research Infrastructure (NRI) Advisory Group.

Gavin Fox-Smith
Non-Executive Director
(Chair-Elect 2025 AGM)



38 years as a leader and champion of Medical Technology in Australia/NZ and Asia.

Gavin is Chair of ANDHealth (Australia's National Digital Health Initiative), Board Director for Bowel Cancer Australia and Board Director for SAN Foundation.

Gavin was previously CEO of Omnigon, a private Australian company in the Ostomy Care market.

Rhythm Bioscience: An attractive investment opportunity



Overview

Rhythm's mission is to detect cancer earlier and reduce the burden of cancer. We are developing and selling proprietary, high value products and services designed to detect cancer earlier.

Growth

Rhythm is solving an important clinical and economic problem. We are preparing for rapid global commercial growth.

Reasons to Invest

1. Multi-product portfolio.
2. Addressing a significant TAM.
3. Poised for revenue growth acceleration.

ersonal use only

Detecting cancer earlier and maintaining wellness

The power of the combination of the Rhythm capabilities and portfolio



Risk Assessment

Determination of risk profile.

Personalised management of health.

Disease Screening

Minimally-invasive detection of disease.


Early detection of disease.

Clinical Performance across the continuum of CRC stages I – IV.

- A powerful combination enabling:**
- Supports preventative measures to maintain wellness.
 - Increase the likelihood of earlier disease detection.
 - Promote better treatment outcomes for detected disease.
 - Potential use in drug clinical studies for patient stratification.
 - Potential for development as companion diagnostic tests.

Suitable for 100s millions of individuals/patients globally

Example: geneType™ bowel cancer risk assessment of the general population to help guide usage of ColoSTAT®. Potentially leads to improved screening compliance, earlier disease detection and improved outcomes.



Personal use only

Our portfolio accesses different biology using similar products

Rhythm products are engineered for affordable quality



Risk Assessment

COLOSTAT®

Disease Screening

Product Format	Reagent kits/service	Reagent kit/service
Patient Sample	Cheek swab	Blood
What we measure	DNA variation and clinical history	Specific proteins
Core technology	SNPs	ELISA
Output	Relative risk over time	Probability of cancer present
Complexity	Simple	Very Simple
Intellectual property	Issued Patents	Issued Patents

Rhythm is targeting a significant global market

A global market of >0.5bn individuals potentially served by the Rhythm product platform.



Genomic Platform: geneType™

Proteomic Platform: ColoSTAT® & Lung Cancer Screening

Healthy individuals seeking information about their personal cancer risk.

Normal Active Risk Assessors
207 million customers

Higher Risk
69 million customers

Unscreened CRC
121 million patients

Unscreened Lung Ca.
40 million patients

Unscreened high risk for CRC cancer investigating disease presence.

Increasingly affecting the younger population and burdening the health system.

Unscreened high risk for lung cancer investigating disease presence.

Higher risk individuals seeking personal risk information.

Key:

■ Area = 1m potential geneType™ customers

■ Area = 1m potential screening customers

Product Launches and upgrades

A diversified mix of development stages and underlying technologies will drive value


Private & Confidential

New Product Release

2nd Gen CRC
geneType™

ColoSTAT®
Symptomatic

Lung cancer
geneType™



Ordering portal
Implementation
complete

geneType™ update

geneType™ update

geneType™ update

geneType™ Report
Upgrade

Product Upgrade Release


Other R&D:

In silico evaluation of combination proteomic and genomic data sets for lung and CRC detection and risk prediction.


Our combined platforms supports a highly comprehensive approach to cancer diagnostics

The potential RHY product portfolio addresses a huge total available market.

Personal use only



Risk Assessment
 Screening
 Triage
 Biopsy
 Surgical Margins
 Drug Management
 Monitoring




Upcoming value inflection points



Personal use only

PRODUCT	ITEM	DESCRIPTION	COMPLETION DATE
ColoSTAT®	Final clinical validation	Evaluation of final testing system	Q3 CY 2025
geneType™	geneType™ strategic partnerships	Establishment of key commercial partners	Q3 CY 2025
geneType™	geneType™ menu expansion	Expansion of existing product portfolio	Q4 CY 2025
ColoSTAT®	Commercialisation	ColoSTAT® In House IVD launch subject to NATA review	Q4 CY 2025
ColoSTAT®	Commercialisation & further development strategic partnerships	Establish ColoSTAT® commercialisation and clinical indication expansion partners	Q1 CY 2026
Lung cancer screening assay	Complete pre-clinical data evaluation	Design of assay prototype	Q2 CY 2026

Capital Raising Overview & Options Offered under Prospectus



Key details of the Offer	
Placement	<ul style="list-style-type: none"> Placement to sophisticated, professional and institutional investors of a maximum of ~\$3.75m, comprising the issue of approximately ~41.6m new, fully paid ordinary Rhythm Biosciences shares (“New Shares”) under ASX listing Rules 7.1 (“Placement”) Directors will participate in the placement, subject to shareholder approval of the Company’s shareholders at the 2025 Annual General Meeting (“AGM”) for \$0.3m comprising the issue of approximately ~3.3m fully paid ordinary Rhythm Biosciences shares. The new shares to be issued under the Placement represent 14.7% of RHY current shares on issue.
Issue Price per New Share	<p>New Shares issued under the placement will be issued at a price of \$0.09 per new share (“Offer Price”), representing a;</p> <ul style="list-style-type: none"> 14.3% discount to the last close price on Wednesday 14 August 2025 of \$0.105 21.3% discount to 5-day VWAP of \$0.114 24.8% discount to 15-day VWAP of \$0.119
Maximum number of New Shares issued under the Offer	41,654,465 New Shares (Including Director participation Shares of 3,333,332)
Maximum proceeds from the Offer	Approximately \$3.75 million (before expenses and costs of the issue).
Maximum number of Shares on issue following the Offer	325,735,086 Ordinary Shares
Lead Manager	CPS Capital Group Pty Ltd

Options (subject to Shareholder Approval at AGM)

Attaching Options offered under the Prospectus for every 1 share applied for and placed, 1 option could be applied for under a separate application, exercise price of \$0.20 per option and term to 30 November 2027. New max. New Options of 52,454,465 to be issued subject to Shareholder Approval at 2025 AGM, incl 10.8m broker options.

Attaching Options – Valuation (subject to shareholder approval)	
Current share price (as at 14 August 2024)	\$0.105
Placement Offer	\$0.090
Discount	14.3%
Discount vs Volume Weighted Average (VWAP) Share Price (ASX)	
5-day VWAP - discount 21.3% #	\$0.1143
15-day VWAP - discount 24.8% #	\$0.1196
30-day VWAP - discount 20.2% #	\$0.1128
Theoretical Offer of Options	
Theoretical Value of Option (Nov 2027)	\$0.045
Option Exercise Price	\$0.200
Theoretical New Issue Price (deducting Value of the Option, per New Share subscribed for)	\$0.045

Indicative Timetable of Placement & Use of Funds

Important dates*		Use of funds		
		Target Raise	Maximum Placement	
Record Date of Trading Halt, Build book Opens	Thursday 14 August 2025	\$1.25m	Up to \$1.5m	
<p>ColoSTAT® Commercialisation & Market Ready</p> <p>Complete the development and production of the ColoSTAT® Multiplex test kit, carry out final testing, and prepare the product for launch by building awareness in the target markets.</p>				
Announcement of Capital Raising and Trading Halt Lifted & Closing Date of Placement	Monday, 18 August 2025	\$1.0m	Up to \$1.25m	
<p>Genetype Geographical expansion with Growth within Existing Verticals</p> <p>Drive growth with geneType™ product suite by expanding into North American and Australian markets, boosting awareness and adoption, and accelerating integration into mainstream healthcare utilising Strategic Partners.</p>				
Settlement of Placement	5.00pm, Thursday 21 August 2025	\$0.9m	Up to \$1.0m	
<p>General Working Capital and capital raising costs</p> <p><i>Day to day working capital requirements and capital raising costs for the Offer</i></p>				
Allotment of New Shares under Placement	Monday, 25 August 2025	\$3.15m	Up to \$3.75m	
<p>Funds raised under the Offer</p>				

* The above dates are indicative only and subject to change. The Company reserves the right, subject to the Corporations Act and the Listing Rules, to extend the Closing Date or to withdraw the Offer at any time without prior notice, in which case all Application Monies will be refunded (without interest) as soon as practicable. Any extension of the Closing Date will have a consequential effect on the issue date of New Shares. All dates and times are references to Melbourne, Australia time.

ersonal use only



Thank you!

david.atkins@rhythmbio.com

www.rhythmbio.com